Channelopathies are a group of genetic, autoimmune, or inflammatory conditions that alter cardiomyocyte ion channel function in a manner that predisposes to bradyarrhythmias or tachyarrhythmias in the absence of a structural heart disorder. Sudden cardiac death may occur.
The ion channels affected include those responsible for the inward sodium or calcium currents and those responsible for the outward potassium current. Either gain of function or loss of function in these ion channels, particularly when the abnormal channels are unevenly distributed, fosters abnormal electrophysiological environments. The abnormal electrophysiology may be favorable to one or both of the following:
Failure of impulse formation or conduction, which may lead to bradyarrhythmias
Re-entry and mechanisms of abnormal automaticity, leading to tachyarrhythmias
The most common genetic channelopathies are the Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), early repolarization syndrome (ERS), idiopathic ventricular fibrillation (IVF), isolated progressive cardiac conduction disease (isolated PCCD), long QT interval syndromes (LQTS), and short QT interval syndrome (SQTS). Together, these genetic channelopathies account for approximately 10% of sudden cardiac deaths.
Autoimmune disorders, including Sjogren syndrome and systemic lupus erythematosus, and inflammatory disorders producing cytokinins that affect cardiomyocyte ion channel function are increasingly being recognized. Anti-Ro/SSA antibodies may produce a long QT interval syndrome by inhibiting the human ether-a-go-go-related gene (hERG) related outward potassium channel, and transplacental exposure to these antibodies in utero is responsible for congenital AV block. Autoimmune antibody production and inflammatory cytokinins may also be responsible for temporal variability in arrhythmia propensities, such as the deleterious effects of fever in patients with Brugada syndrome.
Diagnostic evaluation for genetic channelopathies usually includes ECG, ambulatory cardiac monitoring, and sometimes exercise testing. Genetic testing is frequently done but may not be recommended if its sensitivity for a particular disorder is low. Patients diagnosed with a channelopathy should have regular follow-up with ECG and ambulatory cardiac monitoring to detect occult arrhythmias.
Family members are at risk of disease and should have clinical evaluation (ie, to detect symptoms suggestive of arrhythmia), ECG, ambulatory monitoring, and, sometimes, exercise testing to identify the presence of disease prior to its expression as sudden death. Genetic testing of family members is done when the index case has a known mutation. Typically, parents and siblings are tested first and then other relatives are tested based on results of parent testing and the mode of inheritance (cascade testing). Family members also require ongoing clinical monitoring for development of arrhythmias unless the genetic mutation is absent.
Treatments depend on disease manifestations, but all patients should avoid known triggers (eg, exercise, certain drugs). Patients with clinical or ECG findings of significant ventricular arrhythmias typically require an implantable cardioverter-defibrillator, often one with pacemaker functionality. Some disorders benefit from beta blockade and/or other antiarrhythmic drugs.
